Keratoacanthoma - Кератоакантома
☆ Дар натиҷаҳои соли 2022 Stiftung Warentest аз Олмон, қаноатмандии истеъмолкунандагон аз ModelDerm нисбат ба машваратҳои пулакии телетиб танҳо каме пасттар буд.
Одатан Кератоакантома (Keratoacanthoma)
References
Keratoacanthoma (KA) як варами пӯсти зуд-зуд аст, ки бо афзоиши босуръати худ ва потенсиали худ аз худ бармегардад. Он одатан дар мардони калонсол ва одилона бо таърихи осеби офтоб рух медиҳад. Гарчанде ки бартараф кардани ҷарроҳӣ бо истифода аз экзисия ё ҷарроҳии микрографии Mohs табобати муқаррарӣ аст, имконоти дигари терапевт мавҷуданд.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) варами дараҷаи паст аст, ки дар ғадудҳои муайяни пӯст оғоз меёбад ва дар зери микроскоп ба squamous cell carcinoma (SCC) шабоҳат дорад. Дар бораи он, ки оё КА бояд ҳамчун як шакли SCC инвазивӣ тасниф карда шавад, баҳс идома дорад.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) дуюмин намуди маъмултарини саратон дар байни одамон, махсусан дар байни одамони калонсол аст. Ҷарроҳӣ одатан барои муолиҷаи cSCC истифода мешавад, аммо барои баъзе бемороне, ки ҷарроҳӣ карда наметавонанд ё интихоб намекунанд, имконоти дигар, ба монанди табобати intralesional баррасӣ мешаванд. Табобатҳои анъанавии дохилӣ (methotrexate or 5-fluorouracil) истифода шудаанд, аммо дар бораи равишҳои нав, ба монанди иммунотерапияи интралезоналӣ ва вирусотерапияи онколитикӣ тадқиқот идома дорад. Дар ин ҷо, мо ба табобатҳои гуногуни дохилӣ барои cSCC, аз усулҳои классикӣ то стратегияҳои пешрафта дида мебароем.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Дар зери микроскоп, кератоакантома (keratoacanthoma) ба карциномаҳои ҳуҷайраҳои сквамоза хеле наздик аст. Гарчанде ки баъзе патологҳо кератоакантома (keratoacanthoma) -ро ҳамчун як ҷузъи ҷудогона тасниф мекунанд, на ашаддӣ, тақрибан 6% клиникӣ ва гистологии кератоакантома (keratoacanthoma) ба саратони ҳуҷайраҳои инвазивӣ ва хашмгин табдил меёбанд.
○ Ташхис ва табобат
#Dermoscopy
#Skin biopsy